Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA+BUCY vs BUCY Conditioning for Intermediate-Risk AML Auto-HSCT
NCT02671708Phase 3Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of idarubicin in acute myeloid leukemia (AML) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Leukemia Relapse Rate at 2 years. Started Jan 2016; status: completed.
02
Drugs
idarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02671708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671708.